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Background Previous studies identified the human nonmetastatic gene 23 (NME1, hereafter Nm23-H1) as the first metastasis 
suppressor gene. An inverse relationship between Nm23-H1 and expression of lysophosphatidic acid receptor 1 
gene (LPAR1, also known as EDG2 or hereafter LPA1) has also been reported. However, the effects of LPA1 inhibi-
tion on primary tumor size, metastasis, and metastatic dormancy have not been investigated. 
 Methods The LPA1 inhibitor Debio-0719 or LPA1 short hairpinned RNA (shRNA) was used. Primary tumor size and metasta-
sis were investigated using the 4T1 spontaneous metastasis mouse model and the MDA-MB-231T experimental 
metastasis mouse model (n = 13 mice per group). Proliferation and p38 intracellular signaling in tumors and cell 
lines were determined by immunohistochemistry and western blot to investigate the effects of LPA1 inhibition on 
metastatic dormancy. An analysis of variance-based two-tailed t test was used to determine a statistically signifi-
cant difference between treatment groups. 
 Results In the 4T1 spontaneous metastasis mouse model, Debio-0719 inhibited the metastasis of 4T1 cells to the liver 
(mean = 25.2 liver metastases per histologic section for vehicle-treated mice vs 6.8 for Debio-0719-treated mice, 
73.0% reduction, P < .001) and lungs (mean = 6.37 lesions per histologic section for vehicle-treated mice vs 0.73 
for Debio-0719-treated mice, 88.5% reduction, P < .001), with no effect on primary tumor size. Similar results were 
observed using the MDA-MB-231T experimental pulmonary metastasis mouse model. LPA1 shRNA also inhibited 
metastasis but did not affect primary tumor size. In 4T1 metastases, but not primary tumors, expression of the 
proliferative markers Ki67 and pErk was reduced by Debio-0719, and phosphorylation of the p38 stress kinase was 
increased, indicative of metastatic dormancy. 
 Conclusion The data identify Debio-0719 as a drug candidate with metastasis suppressor activity, inducing dormancy at 
 secondary tumor sites.
  J Natl Cancer Inst 2012;104:1306–1319
Tumor metastasis is a leading contributor to morbidity and mortal-
ity in cancer patients. Studies have shown that on reexpression in 
tumor cell lines, metastasis suppressor genes inhibit metastasis but 
do not substantially reduce primary tumor size (1–6). The human 
nonmetastatic gene 23 (NME1, hereafter Nm23-H1) was the first 
metastasis suppressor gene identified (7–9), and its functional activ-
ity has been confirmed in transfection (9–22) and knockout mouse 
models (23).
The translation of tumor or metastasis suppressor genes as 
anticancer therapeutics has been difficult, and identification of 
targetable proteins with inverse expression patterns as an alternative 
strategy has been explored in preclinical studies with some success 
(24,25). Expression of the lysophosphatidic acid receptor 1 gene 
(LPAR1, also known as EDG2 or hereafter LPA1) was inversely 
associated with expression of Nm23-H1 in tumor cell lines, human 
infiltrating ductal breast carcinomas, and liver tumor tissues 
from wild-type and Nm23-M1 knockout mice (26). Forced LPA1 
expression in tumor cells with high levels of Nm23-H1 expression 
overcame Nm23-H1-mediated suppression of motility in vitro 
(26) and metastasis in vivo (27). Together, these data suggest that a 
LPA1 inhibitor could act as a metastasis suppressor.
LPA1 is a G-protein-coupled receptor for lysophosphatidic acid 
(LPA) (28–34), which is present in submillimolar levels in serum 
(35). LPA1 overexpression in the mammary glands of transgenic 
mice weakly promoted tumorigenesis (36), but studies have shown 
that LPA1-mediated signaling also stimulates tumor cell adhe-
sion, motility, invasion, and metastasis (36–43). Multiple inhibitors 
for LPA1 have been reported (39,44–49), including Debio-0719, 
a selective stereoisomer of a previously identified Ki16425 LPA1 
inhibitor (47). Using both Debio-0719 or short hairpinned RNA 
(shRNA) to decrease expression of LPA1, we investigated the 
effects of LPA1 inhibition on metastasis, primary tumor size, and 
metastatic dormancy using murine 4T1 and human MDA-MB-
231T breast carcinoma cell lines in vitro and in vivo.
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Methods
Cell Lines
Murine mammary carcinoma 4T1 luciferase-labeled cells, a gift 
from Dr Gary Sahagian (Tufts University, Boston, MA), were cul-
tured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, 
Frederick, MD) supplemented with 10% fetal bovine serum. A sub-
line of human MDA-MB-231 cells, designated MDA-MB-231T 
(50), was generously provided by Dr Zach Howard (Laboratory of 
Immunoregulation, National Cancer Institute, Bethesda, MD) and 
was maintained in DMEM supplemented with 10% fetal bovine 
serum. The MDA-MB-231T cell line was used for its reliable in 
vivo experimental metastatic potential.
Clones of 4T1 cells expressing flag-tagged Nm23-H1, 
flag-tagged mouse Nm23 (Nm23-M1), or empty pcDNA3 vec-
tor (Invitrogen) were created. The cDNAs were inserted into the 
BamH1 site in the multiple cloning site of pcDNA3 (Invitrogen), 
and confirmed by DNA sequencing performed by the National 
Cancer Institute Core Services (Bethesda, MD). The plasmids 
were transfected into 4T1 cells using Lipofectamine (Invitrogen, 
Valencia, CA) by the manufacturer’s recommended proto-
col. Forty-eight hours after transfection, cells were cultured in 
DMEM containing 10% fetal bovine serum, 600  µg/mL G418 
(Invitrogen), and the clonal cell lines were subsequently isolated 
and cultured.
LPA1 Inhibitors
Debio-0719 was provided by Debiopharm S.A. (Lausanne, 
Switzerland) and was stored in powder form in the dark at room 
temperature. For all experiments, Debio-0719 was dissolved into 
sterile phosphate-buffered saline, and phosphate-buffered saline 
served as the vehicle control for in vitro and in vivo experiments. 
For the in vitro assays, Debio-0719 was used at a concentration of 
60 nM, which was the half maximal inhibitory concentration for 
antagonist activity (IC50) (data not shown).
LPA1 knockdown was achieved using two validated lentiviral 
shRNA constructs from Sigma-Aldrich (St. Louis, MO) as per the 
manufacturer’s recommendations (catalog no. shclnv-nm 010336). 
Scrambled shRNA constructs were used as a negative control 
(Sigma-Aldrich).
Western Blots
Whole cell lysates were prepared, and protein concentrations were 
determined using the methods given in the Supplementary Materials 
(available online). After proteins were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and transferred to nitro-
cellulose membranes, the membranes were probed with antibodies 
and then visualized on X-ray film (Supplementary Methods and 
Supplementary Table 1, available online).
In Vitro Functional Assays
Cell proliferation was measured by 3-(4,5 dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Supplementary 
Methods, available online). Anchorage-independent growth was 
also assessed (Supplementary Methods, available online). For both 
the cell proliferation and anchorage-independent growth assays, 
five independent experiments were performed.
Migration assays were performed as described [(26) and 
Supplementary Methods, available online]. Briefly, 4T1 or 
MDA-MB-231T cells were incubated in the top compartments 
of Boyden chambers in the presence of vehicle control or vary-
ing concentrations of Debio-0719. The number of cells that had 
migrated through the chamber was quantified. Three independent 
experiments were performed, each in triplicate.
Adhesion assays were performed using the CultureCoat 
Adhesion Protein Array Kit (Trevigen, Gaithersburg, MD) as 
per the manufacturer’s recommended protocol (Supplementary 
Methods, available online).
In Vivo Studies
All mouse experiments were performed under an approved National 
Cancer Institute Animal Use Agreement. Female six-week-old 
Balb/c or athymic NRC nu/nu mice were used.
Spontaneous Metastasis Mouse Model. For the spontaneous 
metastasis experiments, 4T1 cells (parental or modified by stable 
transfection with one of two LPA1 shRNAs, a scrambled shRNA, 
Nm23-H1 constructs, or a vector control construct) were injected 
into the mammary fat pads of female Balb/c mice (n = 10 mice 
per group) (Supplementary Methods, available online). The pri-
mary tumors were measured twice weekly until resection, which 
occurred on days 10 or 14, depending on the experiment. After 
8–11 weeks, depending on the experiment, all lymph nodes, lungs, 
livers, and any other organ suspected of harboring a metastasis 
were collected for histologic analysis. The schedule of randomi-
zation to vehicle (phosphate-buffered saline) or Debio-0719 
(15 mg/kg given subcutaneously twice daily) varied by experi-
ment (Supplementary Methods, available online). Drug treatment 
started on day 2 postinjection of cells for efficacy experiments and 
on day 15 postinjection of cells for adjuvant experiments.
Experimental Pulmonary Metastasis Mouse Model. To inves-
tigate the effect of LPA1 inhibition on metastasis of human breast 
cancer cells in vivo, an experimental pulmonary metastasis study 
was conducted. Athymic NRC nu/nu mice were injected with 5 × 105 
MDA-MB-231T human breast cancer cells via the tail vein [(50) 
and Supplementary Methods, available online]. On the day follow-
ing injection, mice were randomized into three groups contain-
ing 13 mice each. The mice were assigned to one of the following 
treatment groups: vehicle, 15 mg/kg Debio-0719 given twice daily 
subcutaneously or 15mg/kg Debio-0719 given twice daily subcuta-
neously for 35 days followed by administration of vehicle control 
for the remainder of the study. Mice were killed at day 42 by being 
placed in a carbon dioxide chamber, and the lungs were collected 
and fixed in Bouins’ solution (50). Surface metastatic lesions were 
counted on all lungs using a magnifying glass, blinded to the treat-
ment group, before the lungs were embedded in paraffin for histo-
logical analysis (Supplementary Methods, available online).
To investigate the effect of LPA1 inhibition on primary tumor 
growth, 5 × 105 MDA-MB-231T human breast cancer cells were 
implanted into the mammary fat pads of athymic NRC nu/nu mice. 
The day following implantation, mice were randomized into two 
groups of five mice each and treated with vehicle control or 15 mg/
kg Debio-0719 given twice daily subcutaneously. The growth of 
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the primary tumor in the mammary fat pad was measured twice 
weekly by caliper until day 32, at which time they were killed in a 
carbon dioxide chamber. The tumors were then excised, and 5-µm 
sections were stained with hematoxylin and eosin and analyzed by 
a pathologist. Tissues were also used for immunofluorescence or 
immunohistochemical staining (51) for expression of different pro-
teins (Supplementary Methods, available online).
Primary Organ–Conditioned Media
Conditioned medium collected from primary cultures of mam-
mary fat pads, livers, and lungs from Balb/c mice (Supplementary 
Methods, available online) was assayed for soluble cytokine 
expression using cytokine antibody arrays per the manufacturer’s 
protocol (Supplementary Methods, available online).
To model activation of Erk and p38 in vitro, 4T1 cells that 
were plated on type I collagen-coated 35-mm dishes were cultured 
in the presence of vehicle or Debio-0719 for 48 hours and then 
serum-starved overnight. To study activation of phosphorylated 
proteins (Erk and p38) or total protein levels (MKKK1, MKK3, 
MKK4, MKK6, and p27), cells were then stimulated with 20% 
(v/v) conditioned medium from mammary fat pads, livers, or lungs 
before lysis and western blot analysis.
Statistical Analysis
A variety of analyses of variances (ANOVA) were performed on the 
raw or transformed data. Please see the Supplementary Methods 
(available online) for details. A nonparametric Wilcoxon rank sum 
test was used to compare distributions if the data were not nor-
mally distributed and/or the sample sizes were less than 10 mice 
per group. Dunnett method was used to adjust the P values for 
pair-wise comparisons between a control and other treatment. 
Otherwise, Holm method was used to adjust pair-wise P values. 
Because of the multiple tests, we consider a P of .01 as the upper 
limit of what may be interpreted as being statistically significant; a 
strong trend was indicated if P was greater than .01 but less than .05, 
and any P greater than .05 was not statistically significant. Diffuse 
metastasis counts, in which metastases filled the liver and quanti-
tative counts were not feasible, were excluded from the statistical 
analysis because they could potentially introduce bias. Actuarial 
analyses were performed on the survival data using the Kaplan–
Meier method, and curves were compared using the log-rank test. 
Survival times were censored if the mouse was alive at the time of 
the last follow-up. All P values were two-sided.
results
Nm23-H1 Function in a 4T1 Metastasis Model System
Luciferase-expressing 4T1 murine mammary carcinoma cells pro-
duce primary orthotopic mammary tumors and widespread spon-
taneous metastases in immunocompetent mice (52). qRT-PCR 
of 4T1 cells demonstrated expression of LPA family receptors 
LPA1, LPA2, LPA6, and related GPR87, with minor expression 
of LPA3, LPA4, LPA5, and related P2Y10 (data not shown). To 
determine the effect of Nm23 overexpression, 4T1 cells were 
transfected with a vector construct (VC), or the human (H1) or 
murine (M1) homologs of Nm23 (Figure 1, A). Mammary fat pad 
primary tumor sizes from clonal lines at the time of resection were 
comparable between Nm23 and vector transfectants (Figure 1, B). 
Overexpression of Nm23 reduced the number of metastases to the 
liver by 62.4%–69.7% and lungs by 85.1%–94.6% (all P < .05 com-
pared with either 4T1 parental or vector controls) (Figure  1, C 
and D). Expression of LPA1 was reduced in 4T1 cells and primary 
tumors overexpressing Nm23 (Figure 1, E and F).
The molecular structure of Debio-0719, an LPA1 inhibitor, is 
shown (Figure  2, A). The half maximal inhibitory concentration 
for antagonist activity of Debio-0719 for LPA1 was 60 nM, with 
less potent inhibition of LPA3 at 660 nM and LPA2 at 2 µM (data 
not shown). In vitro, Debio-0719 exerted little antiproliferative 
effect on 4T1 cells (data not shown) but inhibited their motility 
(Supplementary Figure 1, available online).
4T1 Spontaneous Metastasis Experiments Using 
Debio-0719
Figure  2, B outlines the first set of 4T1 experiments to test the 
hypothesis that a LPA1 inhibitor would act as a metastasis suppres-
sor. Mice were injected with 4T1 cells in the mammary fat pads on 
day 0 and then randomized to vehicle or Debio-0719 beginning 
2 days postinjection. Mice injected with an Nm23-M1 transfectant 
of 4T1 cells and treated with vehicle served as a positive control for 
metastasis suppressor activity. No antitumor effect of Debio-0719 
was observed in the primary tumors at the time of resection on 
day 10 postinjection (P = .98) (Figure 2, C and D). Therefore, this 
compound would not normally be further studied for drug devel-
opment purposes.
Imaging experiments to determine 4T1 metastatic burden, 
conducted on day 70 postinjection, showed that Debio-0719 had a 
metastasis-suppressive effect (Figure 2, D). Enlarged lymph nodes 
were apparent at the time of necropsy in 22 (55.0%) of 40 vehicle-
treated mice vs 6 (15.0%) of 40 Debio-0719-treated mice and 6 
(15.0%) of 40 mice with 4T1 Nm23-M1a tumors in which metastasis 
was suppressed. A  mean of 25.2 liver metastases per histologic 
section was observed for vehicle-treated mice vs 6.8 for Debio-0719-
treated mice (73.0% reduction, median difference = 18.4 metastases 
per liver, 95% confidence interval [CI] = 12.7 to 24.2, P < .001) and 
5.3 for mice injected with 4T1 Nm23-M1a cells (79.0% reduction, 
median difference = 19.9 metastases per liver, 95% CI = 16.2 to 23.7, 
P < .001) (Figure 2, E). In addition, 6 (15.0%) of 40 vehicle-treated 
mice exhibited diffuse sinusoidal liver metastasis that could not be 
quantified (Supplementary Figure 2, available online) vs 3 (7.5%) of 
40 mice treated with Debio-0719. The mice with diffuse metastases 
were not included in the statistical analysis and therefore represent 
a potential bias because they would all reflect large values. A similar 
trend was observed in lung metastases when a mean of 6.37 lesions 
per histologic section was observed for vehicle-treated mice vs 0.73 
lesions per section for Debio-0719-treated mice (88.5% reduction, 
median difference  =  5.64 metastases per lung, 95% CI  =  4.75 to 
6.53, P < .001) and a 90.1% decline to 0.63 lesions per section for 
mice injected with 4T1 Nm23-M1a, vehicle-treated cells (median 
difference  =  5.74 metastases per lung, 95% CI  =  4.87 to 6.61, 
P < .001) (Figure 2, E and Supplementary Figure 2, available online). 
The number of lung metastases produced by 4T1 Nm23-M1a 
transfectants was not statistically significantly different from those 
produced by 4T1 cells treated with Debio-0719 (P = .72). Debio-0719 
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Figure 1. Effects of nonmetastatic gene 23 (Nm23) suppression on metastasis and lysophosphatidic acid receptor 1 (LPA1) expression in the 4T1 
spontaneous metastasis mouse model. A) Nm23 expression in independent clones of 4T1 murine mammary cells transfected with either a vector 
construct (VC1 and VC2), flag-tagged Nm23-H1 (human ortholog, H1Flg construct; H1a and H1b clones) or flag-tagged Nm23-M1 (mouse ortholog, 
M1Flg construct; M1a and M1b clones) was confirmed by western blot. Tubulin was used as the loading control. B) The size of primary tumors in 
the mammary fat pad formed by the parental 4T1 cell line and each clone on day 10 postinjection (n = 20 Balb/c mice per group) was measured. 
The least-squares mean tumor volume and 95% confidence intervals (whisker bars) are shown.  The mean number of metastases in the (C) liver and 
(D) lungs (bar) was determined at day 70 after orthotopic injection. Metastases were quantified from step sections of tissues stained with hema-
toxylin and eosin. The combined results from two independent experiments are presented. E) Western blot analysis of LPA1 protein expression in 
the transfected clones is shown. Tubulin was used as the loading control. F) The primary tumors from mice injected with the VC1 and M1a clones 
sectioned and underwent immunofluorescence staining for LPA1 protein (green). Tumor nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI, blue). Scale bar = 220 µm.
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Figure 2. The effect of treatment with Debio-0719 on metastasis suppression in the 4T1 spontaneous metastasis mouse model. A) The chemical 
structure of Debio-0719 is depicted. B) The experimental design is outlined. 4T1 cells were injected into the mammary fat pads of Balb/c syngeneic 
mice on day 0. On day 2, mice were randomized to receive vehicle or 15 mg/kg Debio-0719 given subcutaneously twice daily. Primary tumors 
were resected on day 10 postinjection. Mice were killed on day 70 postinjection, and the metastases were quantified. Combined data from two 
independent experiments are shown (n = 40 mice per group). A third experimental group of 4T1 cells transfected with mouse nonmetastatic gene 
23 (Nm23-M1; hereafter M1a cells) was treated with vehicle (n = 40) as a positive control. C) The least-squares mean of the primary tumor size and 
corresponding 95% confidence intervals (whisker bars) at day 10 postinjection are given. D) Representative images of primary tumors on day 10 
postinjection (left panels) and metastatic burden on day 70 postinjection (right panels) taken using a Xenogen In Vivo Imaging System (Caliper 
Life Sciences, Hopkinton, MA) are shown. Please see the color scale to the right of each image, which shows the intensity range of photon flux per 
second from the 4T1 cells. E) The mean number of metastases in step sections of liver and lungs and 95% confidence intervals (whisker bars) are 
shown. *P <.001 compared with the vehicle control-treated mice and was determined by a two-sided t test done with transformed data. The differ-
ences between the mean number of metastases to the liver for Debio-0719 and M1a vehicle-treated groups were not statistically significant. Similar 
results were seen for metastases to the lungs.
was reliably detected in serum, and the weight measurements of 
mice indicated no overt toxic effects (Supplementary Figure  3, 
available online).
To confirm that LPA1 inhibition was responsible for metastatic 
suppression, LPA1 expression in 4T1 cells was stably knocked down 
using shRNAs (Figure  3, A). Knockdown of LPA1 expression by 
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Figure 3. Effect of treatment with Debio-0719 on metastasis in the 4T1 spontaneous metastasis mouse model. A) 4T1 cells were transfected with a 
scramble control short hairpinned RNA (shRNA) or one of two independent shRNAs targeting lysophosphatidic acid receptor 1 (LPA1; clone 1 and 
clone 2). Cell lysates were collected and underwent western blot for LPA1. Tubulin was used as the loading control. B–D) Syngeneic Balb/c mice were 
injected with 4T1 cells into the mammary fat pad on day 0, and primary tumors were resected on day 14 postinjection. The mice were randomized 
to vehicle (n = 10) or 15 mg/kg of Debio-0719 subcutaneously administered twice daily (n = 10) beginning either on days 2 or 15 postinjection. The 
4T1 LPA1 shRNA clone 1 was also injected and treated with vehicle as a positive control (n = 10). B) Primary tumor size was measured, and the 
least-squares mean and 95% confidence intervals (whisker bars) are shown. C–D) The mean number of metastases (bar) in the liver and lungs per 
histologic section on day 56 postinjection was determined.
Table 1. Effect of LPA1 knockdown in a 4T1 mammary carcinoma spontaneous metastasis model*
Scrambled shRNA LPA1 shRNA
Response Vehicle (n = 10) Debio-0179 (n = 9) Vehicle (n = 10) Debio-0179 (n = 10) P
Least-squares mean tumor size, mm3 (95% CI) 400 (290 to 510) 336 (226 to 446) 356 (249 to 469) 357 (247 to 467) .86
No. of mice with diffuse liver metastases 3 1 1 0 –
Median no. of liver metastases per section (95% CI) 24 (19 to 101) 6.25 (2.5 to 13) 13.5 (8.5 to 20) 5.75 (4.0 to 8.0) .01
 % relative to control 100 26.0 56.3 24.0
Median no. of lung metastases per section (95% CI) 2.0 (1.5 to 3.5) 0.5 (0 to 1.5) 1.0 (0 to 1.0) 0 (0 to 1.0)  .004
 % relative to control 100 25.0 50.0 0
*  4T1 murine mammary carcinoma cells were transfected with a scrambled or LPA1 shRNA. Transfectants were injected into the mammary fat pads of syngeneic 
Balb/c mice and after 2 days, mice were randomized to vehicle (phosphate buffered saline) or 15 mg/kg Debio-0719 administered subcutaneously twice daily. The 
size of the primary tumor was measured using calipers on day 14 postinjection, and the primary tumor was resected. The metastases were quantified at day 56 
postinjection. CI = confidence interval; LPA1 = lysophosphatidic acid receptor 1; shRNA = short hairpinned RNA.
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shRNA decreased the in vitro motility of 4T1 cells; Debio-0719 
did not exhibit an additive or synergistic effect when combined with 
shRNA to LPA1 (Supplementary Figure  4, available online). An 
LPA1 shRNA and a scrambled shRNA 4T1 clone were injected into 
the mammary fat pads of syngeneic mice; on day 2 postinjection, 
mice in each treatment group were randomized to vehicle or Debio-
0719 treatment (Table 1). Mean primary tumor sizes on day 14, just 
before surgical removal, were similar (P = .86). LPA1 shRNA knock-
down reduced liver metastases by 43.7%, from 24 to 13.5 metastases 
per histologic section (median difference = 10.5 metastases per liver, 
95% CI = 4.0 to 22, P = .01), and lung metastases by 50.0%, from 2.0 
to 1.0 (median difference = 1.0 metastases per lung, 95% CI = 0.5 to 
3.5, P = .004). Thus, LPA1 inhibition mediated metastasis suppres-
sion. LPA1 shRNA knockdown showed similiar inhibition of lung 
metastases, but it was less effective for liver metastases compared 
with Debio-0719 treatment of mice harboring scrambled shRNA 
4T1 cells. Immunoflourescence staining of LPA1 in shRNA 4T1 cell 
liver metastases demonstrated some reexpression of the target gene 
in vivo (data not shown), a potential reason for the incomplete effect 
of LPA1 shRNA in inhibiting metastasis.
Finally, we determined whether the metastasis-suppressive 
effect of Debio-0719 was independent of treating the primary 
tumor. An experiment similar in design to that shown in Figure 2, B 
was conducted, except that primary tumors were removed on 
day 15 postinjection, and mice were subsequently randomized to 
vehicle or Debio-0719. Primary tumor size among the randomized 
groups was comparable (P  =  .07) (Figure  3, B). Treatment with 
Debio-0719 beginning on day 15 postinjection reduced the num-
ber of liver metastases per histologic section at necropsy on day 56 
postinjection by 51.6% from 27.5 to 13.3 (median difference = 14.2 
metastases per liver, 95% CI = 3.5 to 40.5, P = .01) (Figure 3, C) 
and the number of lung metastases per section by 75.0% from 3.0 
to 0.75 (median difference = 2.3 metastases per lung, 95% CI = 0 
to 3.5, P = .11) (Figure 3, D). These metastatic burdens were not 
statistically significantly different from either Debio-0719 admin-
istered beginning on day 2 postinjection or 4T1 cells expressing an 
LPA1 shRNA and treated with vehicle (P =  .61 and .41, respect-
ively). Taken together, LPA1 inhibition, by shRNA or Debio-0719, 
has antimetastatic function in the 4T1 model system.
LPA1-Mediated Metastasis Suppression Exhibits 
Hallmarks of Dormancy
Histologic sections of primary and metastatic 4T1 tissues were 
analyzed for proliferative and apoptotic markers to determine the 
mechanism of site-specific responsiveness to Debio-0719. The 
Ki67 labeling of primary tumors from mice treated with vehicle or 
Debio-0719 was comparable (P = .86) (Figure 4, A). In contrast, in 
vehicle-treated liver metastases, 15.3% of tumor cells were Ki67 
positive and declined by 64.7% to 5.4% in the Debio-0719-treated 
lesions (median difference = 9.9% of cells positive, 95% CI = 4.1% 
Figure 4. Effect of treatment with Debio-0719 on tumor proliferation in the 4T1 spontaneous metastasis mouse model. The primary tumor and liver 
and lung tissues from the mice used in experiments described in Figure 2, B–E were analyzed for Ki67 as a marker of dormancy. Tissue sections from 
the (A) primary tumors and (B) metastases in the liver (indicated by white dotted lines) from mice injected with 4T1 cells and treated with either 
vehicle control or Debio-0719 (15 mg/kg administered subcutaneously twice daily) underwent immunofluorescence staining for Ki67 (green). Tumor 
nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, blue). The mean expression levels of Ki67 (n = 5 mice per group) were determined 
and were calculated as the mean ratio of Ki67 to DAPI. Corresponding 95% confidence intervals are indicated by the whisker bars. Representative 
images are shown. *P =.005 compared with the vehicle control-treated mice and was determined by a two-sided t test. Scale bar = 220 µm.
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to 15.6%, P = .005) (Figure 4, B). Similar trends were observed in 
4T1 lung metastases (data not shown). No detectable cleaved caspase 
3 was observed at any site (data not shown). Thus, LPA1 pathway 
interruption inhibited tumor proliferation in a site-specific manner, 
suggesting that metastatic dormancy was induced.
Metastatic dormancy is widespread in breast, prostate, and other 
cancers, although the molecular basis is not completely known. 
Dormancy has been proposed to result from the reciprocal down-
regulation of the proliferative Erk Map kinase pathway and upregula-
tion of the p38 stress Map kinase pathway (53,54). The percentage of 
pErk- and phospho-p38-positive tumor cells in primary tumors from 
vehicle- and Debio-0719-treated mice were comparable (P = .55 for 
both pErk and phospho-p38) (Figure  5, A). In contrast, pErk was 
consistently downregulated in Debio-0719-treated liver metastases 
(Figure 5, B), decreasing 86.4%, from 51.5% positivity in the vehicle 
group to 7.0% in the Debio-0719 group (mean difference = 44.5% 
of cells positive, 95% CI = 35.6% to 53.4%, P = .007). Phospho-p38 
positivity showed the opposite pattern in liver metastases, increasing 
from 1.6% of tumor cells in the vehicle group to 50.6% of Debio-
0719-treated tumor cells (mean difference = 49.0% of cells positive, 
95% CI = 38.5% to 59.9%, P = .002). Similar trends were observed in 
4T1 lung metastases (data not shown). The data support the hypoth-
esis that LPA1 inhibition induced metastatic dormancy.
Debio-0719 in a MDA-MB-231T Pulmonary 
Metastasis Model
To confirm the metastasis suppressor function of Debio-0719, the 
low Nm23-H1–expressing, hormone receptor–negative MDA-MB-
231T human breast carcinoma cell line (50) was injected either in 
the mammary fat pad to produce primary tumors or in the tail vein 
to produce experimental lung metastases; mice were randomized to 
vehicle or Debio-0719 beginning on day 2 postinjection. Primary 
tumor size 28 days postinjection was not statistically significantly 
decreased by Debio-0719 (P = .98) (Figure 6, A). Within the 42-day 
time frame of the experimental metastasis assay, 13 (100.0%) of 
13 vehicle-treated mice succumbed to breathing difficulties vs 1 
(7.7%) of 13 mice receiving continuous Debio-0719 (Figure 6, B, 
green vs red). Representative lungs from the vehicle and continuous 
Debio-0719 treatment groups, shown on Figure 6, C, indicate drug-
induced metastasis suppression. The median number of surface lung 
metastases per mouse was 166 in the vehicle group and decreased 
77.1% to 38 with continuous Debio-0719 treatment (median dif-
ference = 128 metastases per lung, 95% CI = 83 to 170, P < .001) 
(Figure  6, D). A  median of seven large metastases (>5 mm in the 
largest dimension) was present in the vehicle group (Figure 6, E) 
and decreased 100.0% to a median of 0 in the Debio-0719 group 
(median difference = 7 metastases per lung, 95% CI = 3 to 8, P < 
.001), indicating suppression of both metastasis number and size.
To determine if continuous Debio-0719 was required for 
metastasis suppression, a third treatment group was treated with 
Debio-0719 for 35  days, at which time 14 (100.0%) of 14 mice 
were alive; thereafter, mice were switched to vehicle. Survival pro-
gressively decreased because mice with labored breathing were 
killed, and pulmonary metastases were evident at necropsy, indi-
cating that suppression of metastasis was reversible (P < .05 for all 
three groups) (Figure 6, B).
The Ki67 proliferative status of MDA-MB-231T experimental 
lung metastases also suggested induction of dormancy by Debio-0719, 
which was reversed when treatment was stopped (Supplementary 
Figure  5, available online). For MDA-MB-231T lung metastases, 
which harbor Ras and B-Raf mutations (55), constitutively activated 
pErk was observed under all conditions. However, Debio-0719 
Figure 5. Effect of Debio-0719 on p38 and Erk activation in the 4T1 spontaneous metastasis model. Tissue sections from the A) primary tumors and 
B) metastases in the liver from mice injected with 4T1 cells and treated with either vehicle control or Debio-0719 (15 mg/kg administered subcutane-
ously twice daily) underwent differential immunohistochemical staining for phospho-Erk (pErk) and phospho-p38 (p-p38). Representative images 
are shown. The mean percentage of cells that stained positive for each antibody are given below each image (n = 5). The corresponding 95% confi-
dence intervals (given in parentheses after the percentage of positive cells below each image) are also reported. *P =.007 and †P =.002 as calculated 
by a two-sided t test indicate a statistically significant difference in protein expression compared with the vehicle control. Scale bar = 220 µm.
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Figure 6. Effect of Debio-0719 on primary tumor size and experimental pulmonary metastasis in the MDA-MB-231T mouse model. A) MDA-MB-231T 
cells were injected into the mammary fat pads of athymic NRC nu/nu mice. The day following implantation, mice were randomized into two groups 
(n = 5) and administered either vehicle control or 15 mg/kg Debio-0719 given subcutaneously twice daily. Mice were killed on day 32. The median 
volume of the primary tumors on day 32 is depicted by the bars. B–D) MDA-MB-231T cells were injected into the tail veins of athymic NRC nu/nu 
mice on day 0. On the following day, the mice were randomized into groups (n = 13 or 14) and treated with vehicle, 15 mg/kg Debio-0719 subcuta-
neously twice daily, or 15 mg/kg Debio-0719 subcutaneously twice daily for 35 days postinjection and then administered vehicle thereafter. Mice 
were killed when breathing distress was observed. B) Kaplan–Meier survival curves are shown, and the number of mice at risk is given in the table 
below. Censored data is indicated by a +. C) Representative pictures of the lungs harvested from the mice in each treatment group are shown. The 
metastases are indicated by the lighter nodules that are apparent on the surface of the lungs. D) The dot plot shows the total number of metastatic 
nodules on the surface of the lungs from mice in each group. Any nodule larger than 5 mm in size was classified separately as a large metastasis, 
and these data are shown separately in (E). The median of each group is indicated by the bar. F) Lung tissues from mice shown in panels (B–D) 
underwent immunohistochemical staining for phospho-p38. Scale bar = 220 µm.
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Figure 7. Effect of lysophosphatidic acid receptor 1 (LPA1) inhibition on p38 activation in vitro. A) 4T1 cells were plated on plastic or type I collagen-
coated cell culture plates, were serum-starved overnight, and then stimulated with 5 µM lysophosphatidic acid (LPA) for 0, 1, 5, or 10 minutes. 
Cell lysates were prepared, and western blotting for total and phosphorylated proteins, including focal adhesion kinase (FAK), phospholipase Cβ 
(PLCβ), Erk1/2, p38, and β actin (loading control), was done. B) 4T1 cells were plated on type I collagen-coated plates, serum-starved overnight, 
and treated with vehicle control or 60 nM Debio-0719. Cells were then stimulated with LPA for 0, 1, 5, or 10 minutes. Cell lysates were prepared, 
and western blotting for total and phosphorylated proteins, including FAK, PLCβ, Erk1/2, p38, and tubulin (loading control), was done. C) 4T1 cells 
were cultured on type I collagen-coated culture plates in the presence of 60 nM Debio-0719 and then serum-starved and stimulated with 20% (v/v) 
conditioned medium (CM) from liver, lungs, or mammary fat pads (MFP) for 10 or 60 minutes. Phosphorylated and total Erk and p38 protein levels 
were determined by western blot. D) 4T1 cells expressing LPA1 short hairpinned (shRNA) or a scrambled control shRNA were cultured on type 
I collagen-coated plates in the presence of 60 nM Debio-0719 or vehicle control and then serum-starved and stimulated with 20% (v/v) conditioned 
medium (CM) from liver, serum-free medium, or LPA only for 1 hour. Phosphorylated and total Erk and p38 protein levels were determined by 
western blot. Tubulin served as the loading control. E) 4T1 cells were cultured as described in panel (C), but lysates were prepared after 10 minutes 
of stimulation with CM, serum-free medium, and probed for total and phosphorylated MAP kinases. The images shown for (A–E) are representa-
tive of three independent experiments. F) Immunofluorescent images of MKK4 expression (green) in primary tumors or liver metastases (white 
dashed line) from either vehicle- or Debio-0719-treated primary tumor and liver tissues from mice used in the experiments described in Figure 2, 
B–E. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, blue). Scale bar = 220 µm.
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elevated phospho-p38 in pulmonary metastases (Figure  6, F). In 
conclusion, the Debio-0719 compound suppressed metastasis in two 
model systems, with p38 activation a consistent hallmark.
Contributors to Increased p38 Signaling in 
Metastatic Dormancy
It is clear that metastatic dormancy in our model systems results 
from signaling that is distinct between the primary tumor and the 
distant metastases, as well as between normal conditions and LPA1 
inhibition. LPA1 interacts with G-protein-coupled receptors to 
signal via multiple downstream pathways conferring tumor motil-
ity and invasion (56–62) as well as other phenotypes. When 4T1 
cells were cultured with serum on plastic, treatment with LPA acti-
vated focal adhesion kinase and phospholipase Cβ (PLCβ) sign-
aling, typical of motility and invasion, as well as Erk (Thr 202/
Tyr 204); no effect on p38 activation was observed (Figure 7, A). 
Histologic analysis indicated that 4T1 cells, in metastasizing to 
the liver, migrated from the portal venules of the liver past the 
basement membrane to the perivascular space, which is enriched 
for type I collagen (Supplementary Figure 6, A, available online); 
similar observations were made in the lung. In agreement with 
this observation, 4T1 cells adhered preferentially to type I colla-
gen (Supplementary Figure 6, B, available online). When 4T1 cells 
were cultured with serum on type I collagen, the resulting signaling 
pattern recapitulated those observed in vivo to show LPA activa-
tion of Erk and diminution of phospho-p38 (Figure 7, A), which 
was inhibited by Debio-0719 treatment (Figure 7, B).
In examining the primary vs metastatic sites, we hypothesized 
that soluble factors present in the mammary fat pad vs liver and 
lung microenvironments may contribute to differential signal-
ing patterns. Conditioned medium was prepared from freshly 
isolated primary cultures of dissected mouse mammary fat pads, 
lung fibroblasts, and parenchymal and nonparenchymal liver cells. 
Using cytokine arrays, 29 cytokines were overexpressed in con-
ditioned media prepared from the lung and liver compared with 
conditioned medium from the mammary fat pad (Supplementary 
Figure 7, available online). The role of these conditioned media in 
metastatic dormancy signaling was investigated by culturing 4T1 
cells on type I  collagen, in the presence of various conditioned 
media (Figure 7, C). Erk was activated in 4T1 cells by lung and 
nonparenchymal liver–conditioned media to a greater degree than 
mammary fat pad–conditioned medium; activation was inhibited 
by Debio-0719 to recapitulate the observed in vivo expression 
trends. For p38, activation was stimulated by Debio-0719 over a 
longer time course, to a greater degree in the presence of liver and 
lung–conditioned media than with mammary fat pad–conditioned 
medium. These expression patterns were not observed when tumor 
cells were plated on plastic or type IV collagen (data not shown). 
Similar trends were observed using scrambled vs LPA1 shRNA 
knockdown 4T1 cells (Figure 7, D). Thus, in vitro culture of 4T1 
cells on type I  collagen in the presence of organ–conditioned 
medium modeled aspects of the in vivo metastasis data.
We further hypothesized that inhibition of LPA1 signaling spe-
cifically promoted p38 activation, regardless of the initiating stimu-
lus. The p38 stress Map kinase is activated by Map2Ks (MKK3, 
MKK6, MKK4, and MKK7 can activate p38 or Jun kinase) and 
Map3Ks (MKKs, TAK, and others) (63). When cultured on type 
I collagen, 4T1 cells expressed increased levels of total MKKK1, 
MKK3, and MKK4 in response to Debio-0719, regardless of the 
presence or type of conditioned medium (Figure 7, E). In agree-
ment with these data, MKK4 expression was upregulated in liver 
metastases of Debio-0719 treated mice (Figure 7, F). Of the phos-
pho-p38 MAP2Ks, MKK3 showed the highest levels of induc-
tion of total protein in response to LPA1 inhibition, and it signals 
directly to p38. One of the known targets of p38 is the cell cycle 
inhibitor p27 (64,65). In agreement with the p38 activation data, 
Debio-0719 enhanced p27 expression in vitro and in vivo (Figure 7, 
E and Supplementary Figure 8, available online). Collectively, the 
data suggest that the hyperactivation of p38 seen in metastatic 
dormancy may result from an abundance of stimulants in the meta-
static microenvironment coupled with overexpression of pathway 
constituents in response to LPA1 inhibition.
Discussion
On the basis of the inverse expression and functional interaction 
of Nm23-H1 and LPA1 (26,27), we hypothesized that a LPA1 
inhibitor could function as a metastasis suppressor. Debio-0719 
statistically significantly inhibited the metastasis of 4T1 murine 
mammary cells to the lungs and liver in four different spontane-
ous metastasis experiments. In the MDA-MB-231T human breast 
carcinoma model, Debio-0719 statistically significantly inhib-
ited the formation of pulmonary metastases. Mouse survival was 
dependent on continuous Debio-0719 administration. These data 
agree with previous reports using various LPA1 pathway inhibi-
tors assessing aspects of metastasis (39,66). LPA1 knockdown also 
statistically significantly prevented metastasis formation in the 4T1 
model system, indicating that the effect of Debio-0719 is largely 
LPA1-specific and that the effects resulting from pharmacological 
inhibition of LPA1 can be recapitulated by knocking down LPA1.
LPA1 inhibition did not statistically significantly reduce pri-
mary tumor size in any experiment we performed, suggesting that 
the LPA1 pathway has no major role in tumor initiation and main-
tenance at the primary site in our model systems. Thus, LPA1 inhi-
bition has the properties of a metastasis suppressor (2,5,67). The 
Debio-0719 compound was nontoxic in our experiments, indicat-
ing that LPA1 can be targeted with a good safety margin; currently, 
various compounds directed at this pathway are under develop-
ment (68). Previous reports have similarly demonstrated distinct 
responses in primary and metastatic sites to changes in tumor cell 
gene expression or drugs (69–71). Because virtually all cancer ther-
apeutics currently in use were validated by short-term inhibition 
of subcutaneous tumor growth as a preclinical endpoint, the LPA1 
inhibitor, Debio-0719, would have been missed by traditional vali-
dation strategies.
Our data also indicate that LPA1 pathway inhibition induced 
aspects of metastatic dormancy. Dormancy, the long-term persis-
tence of subclinical solitary or micrometastatic tumor cells, is poorly 
understood, and it has been characterized as reflecting a balance 
of proliferation and apoptosis, cell cycle quiescence, immunologi-
cal surveillance, or other mechanisms (72–79). In previous studies, 
when tested, dormant tumor cells were insensitive to traditional 
chemotherapeutics (80). A translational goal in breast cancer is to 
induce or sustain a chronic dormant phenotype in tumor cells. In our 
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model systems, LPA1 inhibition reduced the percentage of tumor 
cells transiting the cell cycle only in the metastatic sites—not in the 
primary tumor. Opposing activation of the p38 stress kinase and 
inactivation of the Erk Map kinase have been reported as a potential 
hallmark of dormancy (53,54,81). This pattern was confirmed in the 
metastatic lesions (but not primary tumors) of the two model sys-
tems, with the exception of Erk activation in MDA-MB-231T cells, 
which was constitutively activated by Ras/Raf mutations.
Activation of p38 was a consistent indicator of dormancy in the 
4T1 and MDA-MB-231T models studied. Selective activation of 
p38 in metastatic lesions may result from the multitude of cytokines 
present in the liver and lungs, many of which are known to induce 
p38 stress responses (82–97). We hypothesize that the LPA1 path-
way serves as a gatekeeper for many of these cytokines to acti-
vate p38: Inhibition of LPA1, by Debio-0719 or shRNA targeting 
LPA1, resulted in the upregulation of components of the p38 stress 
kinase pathway at the protein level, including MKK3, MKK4, and 
MKKK1. Thus, signaling that activates p38 from a multitude of 
cytokines present in the metastatic microenvironments could be 
amplified by overexpression of pathway constituents. It is notewor-
thy that MKK4 is a validated metastasis suppressor gene (98); thus, 
one mode of action of a metastasis-suppressive compound may 
be the elevation of other suppressor proteins. To our knowledge, 
Debio-0719 is one of the first compounds to induce metastatic 
dormancy in triple negative breast cancer cells. As a monotherapy, 
this type of inhibitor would be likely to have minimal activity in 
the advanced metastatic setting of phase I trials, but it would be 
expected to be effective in the adjuvant setting, which is similar to 
the design of the preclinical experiments. Adjuvant setting trials 
are large and costly, and therefore they are unsuitable for vali-
dating potential metastasis-suppressive drugs such as Debio-0719. 
Rather, we propose that initial clinical testing use pre- and post-
treatment tumor biopsies to determine the effect of drug on Ki67, 
pErk, and phospho-p38 levels; phase II efficacy trials could enroll 
high-risk patients to determine relapse-free survival.
Our study is not without limitations. Our experiments did not 
determine the duration of the dormancy response to LPA1 inhibi-
tion. Also, Debio-0719 should be tested in other model systems. 
Other LPA1-linked and -independent signaling pathways also 
likely mediate metastatic dormancy, and further studies are neces-
sary to identify these pathways.
In summary, a new drug development paradigm is presented to 
induce tumor dormancy in metastatic sites. Inhibition of signaling by 
the ubiquitous serum phospholipid LPA through the LPA1 receptor 
resulted in tumor withdrawal from the cell cycle in metastatic niches 
and a statistically significant prevention of metastasis formation. 
With such inhibitors in hand, the interaction of dormancy pathways 
and standard of care therapeutics, radiation therapy, patient stress, 
and other important factors can be determined to develop a deeper 
picture of potential preventative and therapeutic scenarios.
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